Genovis Q2 2026 was characterised by strategic expansion following the KPL acquisition and encouraging early progress in Genomics. Net sales came in approximately 4.5% below our estimate, and EBITDA of SEK6.8m fell short of our SEK10.6m forecast (although the underlying figure was SEK10.3m excl. the one-off).
LÄS MER
